AKTX · Akari Therapeutics Plc · Financials
$11.30
+0.42 (+3.86%)
At close · Sep 11
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the "consolidated financial statements") are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.34M
Shares
1.95M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$367.88K
-39.5%
FY2023
Net Income
-$17.3M
+12.6%
FY2025
Operating Margin
-4568.37%
-769pp
FY2023
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$10.57M
+15.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $367.88K | $607.68K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $4.87M | $2.82M | $6.98M | $5.45M | $9.56M | $9.13M | $8.82M | $8.74M | $11.8M | $23.29M | $17.31M | $5.8M | $1.62M | $1.28M | $1.48M | $841K | $247K | — | — | — | — | |
| — | — | — | $8.29M | $8.53M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $8.81M | $9.28M | $9.66M | $11.36M | $13.53M | $8.08M | $9.16M | $8.22M | $11.69M | $11.8M | $9.94M | $5.5M | $303.1K | $2.33M | $2.18M | $1.41M | $545K | — | — | — | — | |
| — | — | $14K | $4000 | $4000 | $4126 | $8907 | $19.21K | $35.85K | $42.4K | $39.94K | $10.16K | $4942 | — | — | — | — | — | — | — | — | |
| — | -$50K | $1.72M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $17.28M | $21.64M | $16.81M | $23.09M | $17.21M | $17.98M | $16.96M | $20.79M | $37.78M | $27.25M | $30.58M | $1.92M | — | — | — | — | — | — | — | — | |
| -$30.99M | -$17.28M | -$21.64M | -$16.81M | -$23.09M | -$17.21M | -$17.98M | -$16.96M | -$20.79M | -$37.78M | -$27.25M | -$30.58M | -$1.92M | -$3.61M | -$3.67M | -$2.25M | -$792K | — | — | — | — | |
| — | — | — | -4568.37% | -3799.36% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$21.63M | -$16.8M | -$23.08M | -$17.21M | -$17.97M | -$16.94M | -$20.75M | -$37.74M | -$27.21M | -$30.57M | -$1.91M | — | — | — | — | — | — | — | — | |
| $136K | $100K | $244K | — | — | — | — | — | — | $0 | $0 | $3.05M | $5436 | — | — | — | — | — | — | — | — | |
| — | $1000 | $8000 | $82K | $46K | $10.6K | $13.62K | $5531 | $222.26K | $175.39K | $143.2K | $20.71K | $91 | — | — | — | — | — | — | — | — | |
| -$1.83M | -$1.03M | $1.85M | $6.8M | $5.34M | -$210.1K | $899.36K | $116.92K | $285.84K | $2.38M | $9.11M | -$14.73M | -$28.25K | -$14K | -$601K | $128K | $117K | — | — | — | — | |
| -$32.82M | -$18.3M | -$19.79M | -$10.01M | -$17.75K | -$17.42M | -$17.08M | -$16.85M | -$20.5M | -$35.4M | -$18.14M | -$45.32M | -$1.95M | — | — | — | — | — | — | — | — | |
| -$1.86M | -$1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | |
| -$30.96M | -$17.3M | -$19.79M | -$10.01M | -$17.75M | -$17.42M | -$17.08M | -$16.85M | -$20.5M | -$35.4M | -$18.14M | -$45.32M | -$1.95M | -$3.62M | -$4.27M | -$2.12M | -$675K | -$1.01M | -$1.44M | -$3.13M | -$1.77M | |
| — | — | — | -2720.47% | -2920.61% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$9.65M | -$3.62M | -$4.3M | -$2.12M | -$675K | — | — | — | — | |
| -$30.55M | -$17.34M | -$19.49M | -$10.28M | -$17.98M | -$17.32M | -$17.38M | -$16.84M | -$20.62M | -$35.36M | -$18.58M | -$45.21M | -$1.87M | — | — | — | — | — | — | — | — | |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$8.00 | -$8.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$8.00 | -$8.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.68B | 597.2M | 244.72M | 156.09M | 5.37M | 3.95M | 2.29M | 1.93M | 1.56M | 1.47M | 1.07M | 106.89K | 26.34K | 15.57K | 14.9K | 14.28K | — | — | — | — |
| shares | — | 1.68B | 597.2M | 244.72M | 156.09M | 5.37M | 3.95M | 2.29M | 1.93M | 1.56M | 1.47M | 1.07M | 106.89K | 26.34K | 15.57K | 14.9K | 14.28K | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.48×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.10×
Peer medians compare against the 249 similar-size Biotechnology companies (of 536 listed).